Death ligands of the Tumor Necrosis Factor (TNF) family are known to induce apoptosis upon binding to their cognate receptors. However, the clinical utility of these cytokines as anticancer agents has been limited due to unacceptable toxicity. TRAIL is a recently isolated death ligand that possesses selective anti-tumor activity against a number of cancer cell lines without signi®cant systemic toxicity. In this report we present evidence that cell lines derived from Ewing's Sarcoma (ES) are uniformly sensitive to TRAIL-mediated apoptosis. Furthermore, unlike TNF-a, treatment with TRAIL fails to induce the anti-apoptotic and pro-in¯ammatory NFkB pathway in the ES cell lines. Our results suggest that TRAIL may prove to be a useful agent for the treatment of Ewing's sarcoma and related peripheral neuroectodermal tumors. Oncogene (2001) 20, 1010 ± 1014.
Keywords: Ewing's sarcoma, TRAIL, Apo2L, apoptosis, MRIT, NF-kB ES is a primitive neuroectodermal tumor that arises in bone or soft tissue (de Alava and Gerald, 2000) . ES is usually associated with a t(11;22)(q24;q12) chromosomal translocation, which results in the production of the EWS-FLI1 fusion protein, a chimeric transcription factor with oncogenic properties (de Alava and Gerald, 2000) . Despite advances in therapy, including the use of high-dose therapy with stem cell transplant, the ®ve-year survival rate for these tumors is only 50%, indicating the need for novel therapeutic approaches (de Alava and Gerald, 2000) .
TRAIL (or Apo-2L) is a recently isolated proapoptotic member of the TNF family which induces rapid apoptosis in a number of transformed cell lines while having no toxicity on a majority of nontransformed cells (Ashkenazi et al., 1999; Walczak et al., 1999) . In vivo administration of TRAIL in mice and non-human primates has been shown to have speci®c anti-tumor activity with no discernible toxicity (Ashkenazi et al., 1999; Walczak et al., 1999) . In this study, we explore the apoptosis and NF-kB-inducing abilities of TRAIL against a panel of ES cell lines. Our results suggest that TRAIL may be a useful therapeutic agent against ES and its role in the immunotherapy of ES and related tumors deserves further study.
In order to characterize the anti-tumor activity of TRAIL against ES cell lines, we expressed the extracellular receptor-binding domain of human TRAIL in insect cells using a baculovirus vector. This construct carried a signal peptide from murine Ig-k chain followed by an isoleucine zipper motif that has been previously shown to help in the stabilization and trimerization of TRAIL (Walczak et al., 1997) . In addition, the fusion protein also carried FLAG and polyhistidine epitope tags between the isoleucine zipper motif and the TRAIL coding region to facilitate detection of the fusion protein.
SF9 insect cells were infected with recombinant baculovirus encoding TRAIL and grown in serum free medium. Seventy-two to 96 h post-infection, the supernatant was collected and analysed for the presence of secreted TRAIL by Western analysis with a Flag antibody. As shown in Figure 1a , a signi®cant amount of secreted TRAIL was detected in the SF9 supernatant. TRAIL was subsequently puri®ed from this supernatant using a Fractogel anion-exchange resin.
The biological activity of recombinant TRAIL was tested on H460 (a lung cancer cell line), which has been previously shown to be highly sensitive to TRAIL (Ashkenazi et al., 1999) . As shown in Figure 1b , incubation of H460 cells with the TRAIL supernatant led to massive cell death, whereas no cytotoxicity was observed in cells incubated with the supernatant collected from SF9 cells infected with a control baculovirus. Essentially similar results were obtained using puri®ed TRAIL.
ES cell lines are uniformly sensitive to TRAIL-induced apoptosis
We next tested the ability of recombinant TRAIL to induce apoptosis in a panel of Ewing's sarcoma cell lines, consisting of SK-N-MC, RD-ES, Grimes, TC-71
Oncogene (2001) and TC-32. All these cell lines carry the pathognomic EWS-FLI1 translocation known to be associated with ES. Treatment of the above cell lines with the TRAIL supernatant led to rapid cell death, which was seen as early as 4 ± 6 h after treatment (Figure 2a, b) . Cells treated with TRAIL demonstrated membrane blebbing, became rounded, and started to detach from the plate (Figure 2b ). No cell death was seen in cells treated with the control supernatant, suggesting the speci®city of the eect (Figure 2b ). Finally, no signi®cant cell death was seen in cells treated with TNF a (10 ± 100 ng/ml) (not shown).
One of the hallmarks of apoptosis is oligonucleosomal fragmentation of DNA. Therefore, to further characterize the nature of cell death induced by TRAIL, we tested its ability to induce DNA fragmentation in ES cell lines. As shown in Figure  2c , RD-ES and TC-71 cells treated with TRAIL demonstrated oligonucleosomal DNA-laddering that was absent in the control treated cells. These results suggest that the ES cell lines treated with TRAIL die by the process of apoptosis.
Previous studies have demonstrated that TRAIL mediates cell death by the activation of caspases (Marsters et al., 1996) . However, death receptors have been also known to mediate caspase-independent forms of cell death under certain circumstances (Vercammen et al., 1997 (Vercammen et al., , 1998 . Therefore, we were interested in determining whether cell death mediated by TRAIL in the Ewing cell lines is dependent on caspase activation. As shown in Figure 2d , TRAIL-mediated cell death in RD-ES and TC-71 cells was completely blocked by zVAD-fmk, a broad-speci®city cell-permeable caspase inhibitor, suggesting the predominant role of caspase activation in this process. Finally, TRAIL-mediated cell death was eectively blocked by a DR5 immunoadhesin, which once again demonstrated the speci®city of this eect (Figure 2c ).
Expression of MRIT/cFLIP in Ewing cell lines
MRIT/cFLIP has been reported to confer resistance to TRAIL-mediated apoptosis (Grith et al., 1998; Leverkus et al., 2000) . Therefore, we used Western analysis to examine MRIT/cFLIP expression in ES cell lines. As shown in Figure 3 , all the ES cell lines tested expressed signi®cant level of cFLIP/MRIT, suggesting that the extreme sensitivity of ES cells to TRAIL is not due to lack of expression of this molecule.
TRAIL fails to activate the NF-kB pathway in ES lines
Three of the TRAIL receptors, DR4/TRAIL-R1, DR5/TRAIL-R2/Killer/TRICK2 and TRAIL-R4/ TRUNDD/DcR2, are capable of activating the NFkB pathway (Chaudhary et al., 1997; . In addition to its role in inducing the transcription of a number of pro-in¯ammatory cytokines, activation of the NF-kB pathway has been known to protect cells against TNFa and TRAILmediated cell death . Therefore, we were interested in comparing the relative abilities of TNFa and TRAIL to activate the NF-kB pathway in ES cells. As shown in Figure 4 , treatment of TC-71, TC-32 and RD-ES cell lines with TRAIL for 30 min failed to activate the NF-kB pathway, while strong activation of this pathway was seen upon treatment with TNFa. These results suggest that TRAIL-mediated apoptosis in ES cells is not accompanied by the activation of the NFkB pathway. This is the ®rst report demonstrating the sensitivity of ES cells towards TRAIL-mediated apoptosis. All the ES cell lines used in the current study are known to harbor the EWS-FLI-1 fusion protein. However, we have observed that retroviral vector-mediated expression of the above fusion protein in NIH3T3 failed to Western analysis using a mouse monoclonal (M2) against the FLAG epitope tag (Sigma), demonstrating the expression of Flag-tagged TRAIL in the supernatant of Sf9 cells infected with a isoleucinezipper TRAIL-encoding baculovirus vector. The vector was generated by cloning the amino acids 95 ± 281 of human TRAIL downstream of murine Ig-k chain signal peptide, an isoleucinezipper trimerization domain (Harbury et al., 1994) , and FLAG and polyhistidine epitope tags. The resulting plasmid was used to generate a recombinant baculovirus using the BAC-TO-BAC baculovirus system (Life Technologies, Inc.) and following the manufacturer's instructions. Sf9 insect cells were infected with the recombinant baculovirus encoding TRAIL or a control baculovirus in sf-900 II serum-free medium (Life Technologies, Inc.) and supernatant containing the secreted protein collected after 72 ± 96 h. After removal of cellular debris by centrifugation, the supernatant was ®ltered and stored in aliquots at 7708C until use. TRAIL was further puri®ed from the supernatant using a Fractogel anion-exchange resin (EMD TMAE) (Novagen). ) were treated with 200 ml of control supernatant or TRAIL containing supernatant for approximately 12 h and DNA fragmentation assay performed essentially as described (Hengere and Mathe, 1996) . The samples are resolved on a 1.8% agarose gel. (d) Inhibition of TRAIL-induced apoptosis by zVAD.fmk and DR5 immunoadhesin. RD-ES and TC-71 cells were treated with a control or TRAIL supernatant (10 ml/well) in the absence or presence of zVAD.fmk (20 mM) or DR5Fc supernatant (10 ml/well). There is an almost complete inhibition of apoptosis in the presence of the inhibitors. DR5 immunoadhesin (DR5Fc) was constructed by cloning the extracellular ligand-binding domain of human DR5/TRAIL-R2 upstream of the murine g-chain Fc region. This construct also carried a FLAG epitope tag at its carboxy terminus. The resulting plasmid was transfected into 293T cells and supernatant containing the secreted protein collected 48 h post-transfection. Expression of DR5Fc was con®rmed by Western analysis using a FLAG antibody that the sensitivity of ES cells to TRAIL is due to lack of expression of cFLIP/MRIT. An alternative explanation for the sensitivity of ES cell lines to TRAIL may be based on their origin from a TRAIL-sensitive neuroectodermal stem cell. It is interesting to note in this regard that in a recent study normal human astrocytes were the only cells found to be sensitive to TRAIL-mediated apoptosis among a panel of 10 nontransformed cells of diverse histological origins (Walczak et al., 1999) .
The death receptors of the TNFR family are known to induce cell death by directly engaging the cellular apoptotic machinery. Thus, unlike chemotherapeutic drugs and radiation therapy, apoptosis induction by the death receptors does not require the function of p53 and related tumor-suppressor genes, which are known to be mutated in a number of human cancers, including some ES (de Alava and Gerald, 2000) . However, despite their ability to induce p53-independent apoptosis, death ligands, such as TNFa and FasL have found limited use as anticancer agents due to unacceptable systemic toxicity combined with poor tumoricidal response. These limitations, in the case of TNFa, can be attributed to the activation of the proin¯ammatory and anti-apoptotic NF-kB pathway (French and Tschopp, 1999) . Unlike TNFa, TRAIL is a relatively weak inducer of the NF-kB pathway and is without signi®cant side-eects on systemic administration in mice and non-human primates (Ashkenazi et al., 1999) . Lack of NF-kB activation may also contribute to the uniform sensitivity of the ES cells to TRAIL-mediated cell death observed in the present study. Taken together, the combination of its excellent cytotoxic activity against ES cells and lack of NF-kB activation suggest that TRAIL may be a promising new agent in the treatment against Ewing's sarcoma either by itself or in combination with chemotherapy. Future studies, aimed at testing its ecacy in the animal models of ES, deserve consideration. A recent report also suggest that human hepatocytes are highly sensitive to TRAIL-mediated apoptosis (Jo et al., 2000) . Therefore, future studies should also test the relative sensitivity of ES cells and human hepatocytes to TRAIL-mediated cell death. ) were treated with 200 ml of control or TRAIL-containing supernatant or TNFa (20 ng/ml) for approximately 30 min and nuclear extract used for electrophoretic mobility shift assay as described previously (Chaudhary et al., 1999) . The position of the induced NF-kB complex is marked with an arrow while an asterisk (*) marks the position of a constitutive NF-kB complex. A weak NF-kB activation was seen in the TC-71 cells after prolonged treatment with TRAIL (data not shown)
